表紙:感染症向け分子診断市場:症候群別、プレックス別、場所別、国別 - COVID-19の影響と予測/分析、エグゼクティブガイドとカスタマイズ(2022年~2026年)
市場調査レポート
商品コード
1086403

感染症向け分子診断市場:症候群別、プレックス別、場所別、国別 - COVID-19の影響と予測/分析、エグゼクティブガイドとカスタマイズ(2022年~2026年)

Molecular Diagnostics for Infectious Disease By Syndrome, Plex, Place and by Country. With COVID-19 Impact & Forecasting/Analysis, and Executive Guides and Customization 2022 - 2026

出版日: | 発行: Howe Sound Research | ページ情報: 英文 574 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=134.29円
感染症向け分子診断市場:症候群別、プレックス別、場所別、国別 - COVID-19の影響と予測/分析、エグゼクティブガイドとカスタマイズ(2022年~2026年)
出版日: 2022年06月08日
発行: Howe Sound Research
ページ情報: 英文 574 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、感染症向け分子診断市場について調査し、市場の概要とともに、疾患別動向、業界概要、症候群別、プレックス別、場所別、国別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 市場ガイド

第2章 イントロダクションと市場の定義

第3章 感染症-疾患別市場分析

  • HIV-ヒト免疫不全ウイルス(AIDS)
  • HBV-B型肝炎
  • HCV-C型肝炎
  • HPV-ヒトパピローマウイルス
  • インフルエンザ
  • CTGC-クラミジア/淋病
  • 結核
  • MRSA-メチシリン耐性黄色ブドウ球菌
  • VRE-バンコマイシン耐性腸球菌
  • 血液スクリーニング
  • COVID-19
  • パンデミック診断

第4章 業界の概要

  • 動的市場における参入機関
  • 臨床検査市場セグメント
  • 業界構造

第5章 主要なMDx企業のプロファイル

  • 1928 Diagnostics
  • Abacus Diagnostica
  • Abbott Laboratories
  • Accelerate Diagnostics
  • Access Bio
  • Ador Diagnostics
  • ADT Biotech
  • Akonni Biosystems
  • Altona Diagnostics
  • Alveo Technologies
  • Anatolia Geneworks
  • Antelope Dx
  • Applied BioCode
  • Assurance Scientific Laboratories
  • Aureum Diagnostics
  • Aus Diagnostics
  • Beckman Coulter Diagnostics
  • Becton, Dickinson and Company
  • Binx Health
  • Biocartis
  • BioFire Diagnostics(bioM?rieux)
  • bioM?rieux Diagnostics
  • Bio-Rad Laboratories, Inc
  • Bosch Healthcare Solutions GmbH
  • Celemics
  • Cepheid(Danaher)
  • Chembio
  • Co Diagnostics
  • Credo Diagnostics Biomedical
  • Cue Health
  • Curetis N.V./Curetis GmbH
  • Detect
  • Diagenode Diagnostics
  • Diascopic
  • Diasorin S.p.A.
  • Eiken Chemical
  • Enzo Biochem
  • Eurofins Scientific
  • Fluxergy
  • Fulgent Genetics
  • Fusion Genomics.
  • Genedrive
  • Genetic Signatures
  • GenMark Dx(Roche)
  • Grifols
  • Grip Molecular Technologies
  • Hibergene Diagnostics
  • Hologic
  • Illumina
  • Immunexpress
  • Inflammatix
  • Invetech
  • Janssen Diagnostics
  • Karius
  • Lexagene
  • LightDeck Diagnostics
  • Lucira Health
  • Luminex Corp
  • LumiraDx
  • Lumos Diagnostics
  • Mammoth Biosciences
  • Maxim Biomedical
  • Meridian Bioscience
  • Mesa Biotech(Thermo Fisher)
  • Millipore Sigma
  • Mindray
  • Mobidiag(Hologic)
  • Molbio Diagnostics
  • Nanomix
  • Novacyt
  • Novel Microdevices
  • Operon
  • Oxford Nanopore Technologies
  • Panagene
  • Pathogenomix
  • Perkin Elmer
  • Prenetics
  • Primerdesign(Novacyt)
  • Prominex
  • Qiagen
  • QuantuMDx
  • Quest Diagnostics
  • Quidel
  • Randox Toxicology
  • Roche Molecular Diagnostics
  • Saw Diagnostics
  • SD Biosensor
  • Seegene
  • Siemens Healthineers
  • SomaLogic
  • Sona Nanotech
  • SpeeDx
  • T2 Biosystems
  • Talis Biomedical
  • Thermo Fisher Scientific Inc.
  • Veramarx
  • Veredus Laboratories
  • Vir
  • Vircell
  • Visby Medical
  • XCR Diagnostics
  • YD Diagnostics
  • Zhejiang Orient Gene Biotech

第6章 市場動向

  • 成長促進要因
  • 成長抑制要因
  • 計装と自動化
  • 診断技術の開発

第7章 感染症向け分子診断:最近の進展

第8章 世界の感染症向け分子診断市場

  • 世界市場概要、国別
  • 世界市場-概要、症候群別
  • 世界市場-概要、プレックス別
  • 世界市場-概要、場所別

第9章 世界の感染症向け分子診断市場-症候群別

  • 呼吸器
  • 胃腸
  • 血液
  • 髄膜炎/脳炎
  • 性感染症
  • その他

第10章 世界の感染症向け分子診断市場-プレックス別

  • シングルプレックス
  • デュプレックス
  • トリプレックス
  • マルチプレックス技術

第11章 世界の感染症向け分子診断市場-場所別

  • 病院検査室
  • 外来検査室
  • POC
  • その他の場所

第12章 付録

図表

Table of Tables

  • Table 1: Classification of HIV Species
  • Table 2: HIV Tests - CMS Codes & Prices
  • Table 3: Current HIV Molecular Tests and Instruments Used
  • Table 4: HBV Tests - CMS Codes & Prices
  • Table 5: HCV Tests - CMS Codes & Prices
  • Table 6: HPV Clearance Rates
  • Table 7: HPV Tests - CMS Codes & Prices
  • Table 8: HPV Tests, Technology, Types
  • Table 9: Types of Influenza Tests
  • Table 10: Influenza Tests - CMS Codes & Prices
  • Table 11: FDA Cleared Molecular Assays for Influenza
  • Table 12: FDA Cleared NAAT CTGC Tests
  • Table 13: CTGC NAAT Target Sequences and Possible False Reactions
  • Table 14: CTGC Tests - CMS Codes & Prices
  • Table 15: FDA Approved MDx Tests for Tuberculosis
  • Table 16: Tuberculosis Tests - CMS Codes & Prices
  • Table 17: FDA Approved Tests for MRSA
  • Table 18: MRSA Tests - CMS Codes & Prices
  • Table 19: FDA Approved Tests for VRE
  • Table 20: VRE Tests - CMS Codes & Prices
  • Table 21: FDA Approved Multiplex Assays
  • Table 22: Characteristics of Coronavirus Pandemic Infections
  • Table 23: COVID-19 Symptoms
  • Table 24: Market Players by Type
  • Table 25: Clinical Laboratory Departments and Segments
  • Table 26: Laboratory Management Focus - Different Approaches
  • Table 27: Key Segmentation Variables Going Forward
  • Table 28: Five Factors Driving Growth
  • Table 29: Four Factors Limiting Growth
  • Table 30: Key Diagnostic Laboratory Technology Trends
  • Table 31: - Global Market by Region
  • Table 32: Global Market by Syndrome
  • Table 33: Global Market by Plex
  • Table 34: Global Market by Place
  • Table 35: Respiratory by Country
  • Table 36: Gastrointestinal by Country
  • Table 37: Blood by Country
  • Table 38: Meningitis/Encephalitis by Country
  • Table 39: Sexually Transmitted Disease by Country
  • Table 40: Other by Country
  • Table 41: Single Plex by Country
  • Table 42: Duplex by Country
  • Table 43: Triplex by Country
  • Table 44: Multiplex by Country
  • Table 45: Hospital Lab by Country
  • Table 46: Outpatient Lab by Country
  • Table 47: POC by Country
  • Table 48: Other Place by Country
  • Table 49: 2022 Clinical Lab Fee Schedule

Table of Figures

  • Figure 1: Global Health Care Spending
  • Figure 2: The Lab Test Pie
  • Figure 3: HIV Virion
  • Figure 4: Diagram of the HIV Replication Cycle
  • Figure 5: The Structure of the HBV Virus
  • Figure 6: Hepatitis B Replication
  • Figure 7: Structure of the HCV Virus
  • Figure 8: HCV Replication Cycle
  • Figure 9: Structure of the Influenza Virion
  • Figure 10: Influenza Replication
  • Figure 11: Scanning Electronmicrograph of Tuberculosis
  • Figure 12: Percentage of World Population Over 65
  • Figure 13: Chart Infectious Disease Decline
  • Figure 14: Global Market Shares Chart
  • Figure 15: Global Market by Syndrome - Base vs. Final
  • Figure 16: Global Market by Syndrome Base Year
  • Figure 17: Global Market by Syndrome End Year
  • Figure 18: Syndrome Share by Year
  • Figure 19: Syndrome Segments Growth
  • Figure 20: Global Market by Plex - Base vs. Final
  • Figure 21: Global Market by Plex Base Year
  • Figure 22: Global Market by Plex End Year
  • Figure 23: Plex Share by Year
  • Figure 24: Plex Segments Growth
  • Figure 25: Global Market by Place - Base vs. Final
  • Figure 26: Global Market by Place Base Year
  • Figure 27: Global Market by Place End Year
  • Figure 28: Place Share by Year
  • Figure 29: Place Segments Growth
  • Figure 30: Respiratory Growth
  • Figure 31: Gastrointestinal Diagnostics Growth
  • Figure 32: Blood Growth
  • Figure 33: Meningitis/Encephalitis Growth
  • Figure 34: Sexually Transmitted Disease Growth
  • Figure 35: Other Growth
  • Figure 36: Single Plex Growth
  • Figure 37: Duplex Growth
  • Figure 38: Triplex Growth
  • Figure 39: Multiplex Growth
  • Figure 40: Hospital Lab Growth
  • Figure 41: Outpatient Lab Growth
  • Figure 42: POC Growth
  • Figure 43: Other Place Growth
目次

OVERVIEW:

COVID-19 Drives a surge in demand but what is the long term impact? The microbiology lab my disappear while multiplex takes center stage.

The Molecular Diagnostics - Infectious Disease sector of the clinical diagnostics industry is poised for record growth. A market that just keeps on growing but is spiking as an enormous C19Dx demand sweeps over the globe. Find out what the numbers are in this informative report. And find out about the exciting developments in multiplex assays which threaten to change diagnosis and treatment while limiting the threat of anti microbial drug resistance.

Infectious disease testing directly benefits from the explosion in biotechnology, especially genomics. Learn all about it in this new report from Howe Sound Research. A range of dynamic trends are pushing market growth and company valuations. Trends like:

  • Multiplex testing
  • pathogen evolution and pandemics
  • biotechnology advances in genetics
  • climate change
  • globalization
  • the rise of rapid testing

Exciting technical developments especially in the seesaw between nucleic acid testing and immunoassay, hold the promise of a dynamic, growing and evolving world market that holds the promise of diagnostics taking the lead in infectious disease eradication.

The report has hundreds of pages of information including a complete list of Current 2020 United States Medicare Fee Payment Schedules to help sharpen your pricing. Again, assistance in using the information is normally provided without additional charges. The report includes detailed breakouts for 15 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report.

All report data is available in Excel format on request.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

1. Market Guides

  • 1.1. Strategic Situation Analysis
  • 1.2. Guide for Executives, Marketing, Sales and Business Development Staff
  • 1.3. Guide for Management Consultants and Investment Advisors

2. Introduction and Market Definition

  • 2.1. What are Molecular Diagnostics?
  • 2.2. The Diagnostics Revolution
  • 2.3. Market Definition
    • 2.3.1. Revenues
  • 2.4. Methodology
    • 2.4.1. Methodology
    • 2.4.2. Sources
    • 2.4.3. Authors
  • 2.5. Perspective: Healthcare and the IVD Industry
    • 2.5.1. Global Healthcare Spending
    • 2.5.2. Spending on Diagnostics
    • 2.5.3. Important Role of Insurance for Diagnostics

3. The Infectious Diseases - Market Analysis by Disease

  • 3.1. HIV - Human Immunodeficiency Virus (AIDS)
    • 3.1.1. Virology
      • 3.1.1.1. Classification
      • 3.1.1.2. Structure and genome
      • 3.1.1.3. Tropism
      • 3.1.1.4. Replication cycle
      • 3.1.1.5. Genetic variability
    • 3.1.2. Diagnosis
    • 3.1.3. Testing
      • 3.1.3.1. Antibody tests
      • 3.1.3.2. Point of Care Tests (POCT)
      • 3.1.3.3. Antigen Tests
      • 3.1.3.4. Nucleic acid-based tests (NAT)
      • 3.1.3.5. Other tests used in HIV treatment
    • 3.1.4. Market Opportunity Analysis
  • 3.2. HBV - Hepatitis B
    • 3.2.1. Virology
      • 3.2.1.1. Genome
      • 3.2.1.2. Pathogenesis
      • 3.2.1.3. Hepatitis B virus replication
      • 3.2.1.4. Serotypes and genotypes
    • 3.2.2. Mechanisms
    • 3.2.3. Diagnosis
    • 3.2.4. Market Opportunity Analysis
  • 3.3. HCV - Hepatitis C
    • 3.3.1. Taxonomy
    • 3.3.2. Structure
      • 3.3.2.1. Genome
    • 3.3.3. Molecular biology
    • 3.3.4. Replication
    • 3.3.5. Genotypes
      • 3.3.5.1. Clinical importance
    • 3.3.6. Market Opportunity Analysis
  • 3.4. HPV - Human papillomavirus
    • 3.4.1. Virology
      • 3.4.1.1. E6/E7 proteins
      • 3.4.1.2. Role in cancer
      • 3.4.1.3. E2 research
      • 3.4.1.4. Latency period
      • 3.4.1.5. Clearance
    • 3.4.2. Diagnosis
      • 3.4.2.1. Cervical testing
      • 3.4.2.2. Oral testing
      • 3.4.2.3. Testing men
      • 3.4.2.4. Other testing
    • 3.4.3. Market Opportunity Analysis
  • 3.5. Influenza
    • 3.5.1. Virology
      • 3.5.1.1. Types of virus
      • 3.5.1.2. Influenzavirus A
      • 3.5.1.3. Influenzavirus B
      • 3.5.1.4. Influenzavirus C
      • 3.5.1.5. Structure, properties, and subtype nomenclature
      • 3.5.1.6. Replication
    • 3.5.2. Testing
      • 3.5.2.1. Advantages/Disadvantages of Molecular Assays
    • 3.5.3. Market Opportunity Analysis
  • 3.6. CTGC - Chlamydia/Gonorhea
    • 3.6.1. Gonorrhea
      • 3.6.1.1. Diagnosis
      • 3.6.1.2. Screening
    • 3.6.2. Chlamydia
      • 3.6.2.1. Diagnosis
      • 3.6.2.2. Screening
    • 3.6.3. Testing
      • 3.6.3.1. Nucleic acid amplification tests (NAATs).
      • 3.6.3.2. Performance of NAAT Tests
    • 3.6.4. Market Opportunity Analysis
  • 3.7. Tuberculosis
    • 3.7.1. Mycobacteria
    • 3.7.2. Diagnosis
      • 3.7.2.1. Active tuberculosis
      • 3.7.2.2. Latent tuberculosis
    • 3.7.3. Epidemiology
    • 3.7.4. Molecular Diagnostic Tests
    • 3.7.5. Market Opportunity Analysis
  • 3.8. MRSA - Methicillin-resistant Staphylococcus aureus
    • 3.8.1. Diagnosis
    • 3.8.2. FDA Approved Molecular Tests
    • 3.8.3. Market Opportunity Analysis
  • 3.9. VRE - Vancomycin-resistant Enterococcus
    • 3.9.1. FDA Approved MDx Tests for VRE
    • 3.9.2. Market Opportunity Analysis
  • 3.10. Blood Screening
    • 3.10.1. Collection and Testing
    • 3.10.2. FDA Approved Multiplex Assays
    • 3.10.3. Market Opportunity Analysis
  • 3.11. COVID-19
    • 3.11.1. Signs and symptoms
    • 3.11.2. Transmission
    • 3.11.3. Diagnosis
    • 3.11.4. Prevention
    • 3.11.5. Management
    • 3.11.6. Prognosis
  • 3.12. Pandemic Diagnostics
    • 3.12.1. Risk Management - Spark and Spread
    • 3.12.2. Dx Technology - Nucleic Acid Based
    • 3.12.3. Dx Technology - Immunoassay & Serology
    • 3.12.4. Time to Market and Preparedness Issues
    • 3.12.5. Unrecognized Role of Multiplex in Pandemic Mangement

4. Industry Overview

  • 4.1. Players in a Dynamic Market
    • 4.1.1. Academic Research Lab
    • 4.1.2. Diagnostic Test Developer
    • 4.1.3. Instrumentation Supplier
    • 4.1.4. Distributor and Reagent Supplier
    • 4.1.5. Independent Testing Lab
    • 4.1.6. Public National/regional lab
    • 4.1.7. Hospital lab
    • 4.1.8. Physician Office Labs
    • 4.1.9. Audit Body
    • 4.1.10. Certification Body
  • 4.2. The Clinical Laboratory Market Segments
    • 4.2.1. Traditional Market Segmentation
    • 4.2.2. Laboratory Focus and Segmentation
  • 4.3. Industry Structure
    • 4.3.1. Hospital Testing Share
    • 4.3.2. Economies of Scale
      • 4.3.2.1. Hospital vs. Central Lab
    • 4.3.3. Physician Office Lab's
    • 4.3.4. Physician's and POCT

5. Profiles of Key MDx Companies

  • 5.1. 1928 Diagnostics
  • 5.2. Abacus Diagnostica
  • 5.3. Abbott Laboratories
  • 5.4. Accelerate Diagnostics
  • 5.5. Access Bio
  • 5.6. Ador Diagnostics
  • 5.7. ADT Biotech
  • 5.8. Akonni Biosystems
  • 5.9. Altona Diagnostics
  • 5.10. Alveo Technologies
  • 5.11. Anatolia Geneworks
  • 5.12. Antelope Dx
  • 5.13. Applied BioCode
  • 5.14. Assurance Scientific Laboratories
  • 5.15. Aureum Diagnostics
  • 5.16. Aus Diagnostics
  • 5.17. Beckman Coulter Diagnostics
  • 5.18. Becton, Dickinson and Company
  • 5.19. Binx Health
  • 5.20. Biocartis
  • 5.21. BioFire Diagnostics (bioMérieux)
  • 5.22. bioMérieux Diagnostics
  • 5.23. Bio-Rad Laboratories, Inc
  • 5.24. Bosch Healthcare Solutions GmbH
  • 5.25. Celemics
  • 5.26. Cepheid (Danaher)
  • 5.27. Chembio
  • 5.28. Co Diagnostics
  • 5.29. Credo Diagnostics Biomedical
  • 5.30. Cue Health
  • 5.31. Curetis N.V. / Curetis GmbH
  • 5.32. Detect
  • 5.33. Diagenode Diagnostics
  • 5.34. Diascopic
  • 5.35. Diasorin S.p.A.
  • 5.36. Eiken Chemical
  • 5.37. Enzo Biochem
  • 5.38. Eurofins Scientific
  • 5.39. Fluxergy
  • 5.40. Fulgent Genetics
  • 5.41. Fusion Genomics.
  • 5.42. Genedrive
  • 5.43. Genetic Signatures
  • 5.44. GenMark Dx (Roche)
  • 5.45. Grifols
  • 5.46. Grip Molecular Technologies
  • 5.47. Hibergene Diagnostics
  • 5.48. Hologic
  • 5.49. Illumina
  • 5.50. Immunexpress
  • 5.51. Inflammatix
  • 5.52. Invetech
  • 5.53. Janssen Diagnostics
  • 5.54. Karius
  • 5.55. Lexagene
  • 5.56. LightDeck Diagnostics
  • 5.57. Lucira Health
  • 5.58. Luminex Corp
  • 5.59. LumiraDx
  • 5.60. Lumos Diagnostics
  • 5.61. Mammoth Biosciences
  • 5.62. Maxim Biomedical
  • 5.63. Meridian Bioscience
  • 5.64. Mesa Biotech (Thermo Fisher)
  • 5.65. Millipore Sigma
  • 5.66. Mindray
  • 5.67. Mobidiag (Hologic)
  • 5.68. Molbio Diagnostics
  • 5.69. Nanomix
  • 5.70. Novacyt
  • 5.71. Novel Microdevices
  • 5.72. Operon
  • 5.73. Oxford Nanopore Technologies
  • 5.74. Panagene
  • 5.75. Pathogenomix
  • 5.76. Perkin Elmer
  • 5.77. Prenetics
  • 5.78. Primerdesign (Novacyt)
  • 5.79. Prominex
  • 5.80. Qiagen
  • 5.81. QuantuMDx
  • 5.82. Quest Diagnostics
  • 5.83. Quidel
  • 5.84. Randox Toxicology
  • 5.85. Roche Molecular Diagnostics
  • 5.86. Saw Diagnostics
  • 5.87. SD Biosensor
  • 5.88. Seegene
  • 5.89. Siemens Healthineers
  • 5.90. SomaLogic
  • 5.91. Sona Nanotech
  • 5.92. SpeeDx
  • 5.93. T2 Biosystems
  • 5.94. Talis Biomedical
  • 5.95. Thermo Fisher Scientific Inc.
  • 5.96. Veramarx
  • 5.97. Veredus Laboratories
  • 5.98. Vir
  • 5.99. Vircell
  • 5.100. Visby Medical
  • 5.101. XCR Diagnostics
  • 5.102. YD Diagnostics
  • 5.103. Zhejiang Orient Gene Biotech

6. Market Trends

  • 6.1. Factors Driving Growth
    • 6.1.1. New Genotypes Creating New Markets
    • 6.1.2. Aging Population a Boon for All Diagnostics
    • 6.1.3. Developing World Driving ID Dx Growth
    • 6.1.4. Point of Care - Why Centralization is Losing Steam
    • 6.1.5. Self Testing
    • 6.1.6. The Need for Speed
    • 6.1.7. The COVID Pandemic
  • 6.2. Factors Limiting Growth
    • 6.2.1. Lower Costs
    • 6.2.2. Infectious Disease is Declining
    • 6.2.3. Wellness Hurts
    • 6.2.4. Economic Growth improves Living Standards
  • 6.3. Instrumentation and Automation
    • 6.3.1. Instruments Key to Market Share
    • 6.3.2. The Shrinking Machine
    • 6.3.3. Multiplex, Point of Care and The Speed Factor
  • 6.4. Diagnostic Technology Development
    • 6.4.1. The Sepsis Testing Market - A New Direction?
    • 6.4.2. POCT/Self Testing as a Disruptive Force
    • 6.4.3. The Genetics Play - One Test for All Known Infections
    • 6.4.4. Antibiotic Resistance Genes - Simplifying Diagnostics

7. Molecular Dx - Infectious Disease Recent Developments

  • 7.1. Recent Developments - Importance and How to Use This Section
    • 7.1.1. Importance of These Developments
    • 7.1.2. How to Use This Section
  • 7.2. BioMérieux Invests in Sepsis Dx Startup Weezion
  • 7.3. Domus Diagnostics to Launch POC MDx Test System
  • 7.4. Proof Dx Plans Infectious Disease, Oncology Tests for CRISPR-Based POC
  • 7.5. Oxford Nanopore Diagnostics to Develop Clinical Tools
  • 7.6. Pathogenomix Developing Infectious Disease Platform Using NGS
  • 7.7. COVID-19 Accelerating Trend Toward Pharmacy-Based Testing
  • 7.8. Co-Diagnostics Seeks FDA EUA for At-Home PCR Diagnostic
  • 7.9. Sense Biodetection to Debut Instrument-Free Point-of-Care MDx
  • 7.10. Home Test Company Prenetics to go Public
  • 7.11. Roche to Acquire TIB Molbiol to Expand Infectious Disease Portfolio
  • 7.12. Lucira Health Posts Revenue Growth on OTC C19 Test
  • 7.13. BforCure Preparing Multiple Panels for Point-of-Care qPCR Platform
  • 7.14. Talis Biomedical Discusses Point-of-Care
  • 7.15. Roche to Acquire GenMark Diagnostics for $1.8B
  • 7.16. Pandemic Pushes Handheld qPCR Devices Closer to Commercialization
  • 7.17. Hologic to Acquire Mobidiag
  • 7.18. Lucira Health Focuses on User Friendly Approach to Home Testing
  • 7.19. Infectious Disease Dx Firm Talis Biomedical Raises $254M in IPO
  • 7.20. Fluidigm Plans 'Durable' Diagnostics, Clinical Business
  • 7.21. Thermo Fisher Scientific to Acquire Mesa Biotech for Up to $550M
  • 7.22. Mammoth Biosciences Developing Pathogen Detection Tech
  • 7.23. Illumina, IDbyDNA Developing Sequencing-Based Respiratory Tests
  • 7.24. Scanogen Developing 90 Minute Infection Test
  • 7.25. Malaria Assays Use CRISPR for Point-of-Care Multispecies Detection
  • 7.26. FDA Provides Self Testing SARS-CoV-2 EAU Guidance
  • 7.27. Mammoth Biosciences Announces Rapid, CRISPR-Based COVID-19 Diagnostic
  • 7.28. Genetic Signatures Gets CE Mark for Coronavirus Molecular Test
  • 7.29. Qiagen Respiratory Panel with Coronavirus Receives CE Mark
  • 7.30. Lumos Diagnostics Closes $15M Series A Funding
  • 7.31. Fusion Genomics to Assess NGS-Based Respiratory Tract Infection Assay

8. The Global Market for Molecular Diagnostics Infectious Disease

  • 8.1. Global Market Overview by Country
    • 8.1.1. Table - Global Market by Country
    • 8.1.2. Chart - Global Market by Country
  • 8.2. Global Market by Syndrome - Overview
    • 8.2.1. Table - Global Market by Syndrome
    • 8.2.2. Chart - Global Market by Syndrome - Base/Final Year Comparison
    • 8.2.3. Chart - Global Market by Syndrome - Base Year
    • 8.2.4. Chart - Global Market by Syndrome - End Year
    • 8.2.5. Chart - Global Market by Syndrome - Share by Year
    • 8.2.6. Chart - Global Market by Syndrome - Segments Growth
  • 8.3. Global Market by Plex - Overview
    • 8.3.1. Table - Global Market by Plex
    • 8.3.2. Chart - Global Market by Plex - Base/Final Year Comparison
    • 8.3.3. Chart - Global Market by Plex - Base Year
    • 8.3.4. Chart - Global Market by Plex - End Year
    • 8.3.5. Chart - Global Market by Plex - Share by Year
    • 8.3.6. Chart - Global Market by Plex - Segments Growth
  • 8.4. Global Market by Place - Overview
    • 8.4.1. Table - Global Market by Place
    • 8.4.2. Chart - Global Market by Place - Base/Final Year Comparison
    • 8.4.3. Chart - Global Market by Place - Base Year
    • 8.4.4. Chart - Global Market by Place - End Year
    • 8.4.5. Chart - Global Market by Place - Share by Year
    • 8.4.6. Chart - Global Market by Place - Segments Growth

9. Global MDx Infectious Disease Markets - By Syndrome

  • 9.1. Respiratory
    • 9.1.1. Table Respiratory - by Country
    • 9.1.2. Chart - Respiratory Growth
  • 9.2. Gastrointestinal
    • 9.2.1. Table Gastrointestinal - by Country
    • 9.2.2. Chart - Gastrointestinal Growth
  • 9.3. Blood
    • 9.3.1. Table Blood - by Country
    • 9.3.2. Chart - Blood Growth
  • 9.4. Meningitis/Encephalitis
    • 9.4.1. Table Meningitis/Encephalitis - by Country
    • 9.4.2. Chart - Meningitis/Encephalitis Growth
  • 9.5. Sexually Transmitted Disease
    • 9.5.1. Table Sexually Transmitted Disease - by Country
    • 9.5.2. Chart - Sexually Transmitted Disease Growth
  • 9.6. Other
    • 9.6.1. Table Other - by Country
    • 9.6.2. Chart - Other Growth

10. Global MDx Markets for Infectious Disease - by Plex

  • 10.1. Single Plex
    • 10.1.1. Table Single Plex - by Country
    • 10.1.2. Chart - Single Plex Growth
  • 10.2. Duplex
    • 10.2.1. Table Duplex - by Country
    • 10.2.2. Chart - Duplex Growth
  • 10.3. Triplex
    • 10.3.1. Table Triplex - by Country
    • 10.3.2. Chart - Triplex Growth
  • 10.4. Multiplex Technology
    • 10.4.1. Table Multiplex - by Country
    • 10.4.2. Chart - Multiplex Growth

11. Global MDx Infectious Disease Markets - by Place

  • 11.1. Hospital Lab
    • 11.1.1. Table Hospital Lab - by Country
    • 11.1.2. Chart - Hospital Lab Growth
  • 11.2. Outpatient Lab
    • 11.2.1. Table Outpatient Lab - by Country
    • 11.2.2. Chart - Outpatient Lab Growth
  • 11.3. POC
    • 11.3.1. Table POC - by Country
    • 11.3.2. Chart - POC Growth
  • 11.4. Other Place
    • 11.4.1. Table Other Place- by Country
    • 11.4.2. Chart - Other Place Growth

12. Appendices

  • 12.1. United States Medicare System: 2022 Clinical Laboratory Fees Schedule